LNTH - Lantheus inks exclusive rights agreement with Allegheny Health

Lantheus Holdings (LNTH) announces a strategic collaboration with Allegheny Health Network ((AHN)) for the use of its Microbubbles in Combination with ultrasound assisted gene therapy for the development of a proposed treatment for xerostomia, a lack of saliva production leading to dry mouth.Under the agreement, Lantheus’ microbubbles will be used in combination with AHN’s ultrasound-assisted non-viral gene transfer ((UAGT)) technology for the development of a treatment.Allegheny will be solely responsible for all development work, future regulatory submissions and commercialization.The companies did not provide further financial details, but said that the deal terms include a transfer price and royalties.

For further details see:

Lantheus inks exclusive rights agreement with Allegheny Health